ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.69
0.12 (1.40%)
▲
5d:
+2.24%
30d:
+2.72%
90d:
-36.06%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 8.2/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 12.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ADMA shows positive signals but monitor for confirmation. Market pricing in 12.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.82
Based on 13.3% avg growth
INTRINSIC VALUE TODAY
$14.79
41.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.69, which is considered extended relative to its 30-day fair value range of $7.94 to $8.52. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.6) compared to its historical average (12.9). Remarkably, the market is currently pricing in an annual earnings decline of 12.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $8.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+105.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ADMA is in a strong downtrend. The price is approaching resistance at $8.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ADMA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $17.60 (+105.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.94 -
$8.52
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 105.4% below Wall St target ($17.60)
Trading Range Analysis
30-Day Trading Range
$7.94 -
$8.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.02
Resistance Level
$8.90
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.59
Wall Street Target
$17.60
(+105.4%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-12.6% cheaper
PE vs Historical
8.6 vs 12.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-12.6%
(market-implied from PE analysis)
1-Year Target
$7.71
(-10%)
2-Year Target
$6.94
(-19%)
3-Year Target
$6.25
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→13)
$9.38
(+10%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 22.6%)
$40.08
(+368%)
Base:
(SPY PE: 8.6, Growth: 22.6%)
$15.81
(+85%)
Bear:
(PE: 7.3, Growth: 22.6%)
$13.44
(+57%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 12.22 | Current EPS (TTM): $0.68
Bull Case
$13.41
(+57%)
Analyst growth 46.7%, PE expands to 13.4
Base Case
$12.19
(+42%)
Market implied 46.7%, PE stable at 12.2
Bear Case
$5.65
(-34%)
Severe decline -20.0%, PE contracts to 10.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.6 to 12.9
Stabilization Target:
$12.87
(+50.1%)
PE Expansion Potential:
+50.1%
Share & Embed Analysis
Last updated: June 23, 2026 3:52 PM ET
Data refreshes hourly during market hours. Next update: 4:52 PM
Data refreshes hourly during market hours. Next update: 4:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 54 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 67 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
